Cempra to Present at the Jefferies 2016 Healthcare Conference
02 juin 2016 08h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., June 02, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
25 mai 2016 16h30 HE
|
Melinta Therapeutics, Inc.
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM) All efficacy outcome measures favored solithromycin Management to host Q&A webcast and conference call tomorrow at 8:00...
Cempra to Present Solithromycin IV Data at ATS 2016
12 mai 2016 16h05 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., May 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports First Quarter 2016 Financial Results and Provides Corporate Update
01 mai 2016 17h05 HE
|
Melinta Therapeutics, Inc.
NDA submissions completed for solithromycin intravenous and oral capsule formulations in the treatment of community-acquired pneumonia Management to host webcast and conference call tomorrow at...
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
01 mai 2016 17h00 HE
|
Melinta Therapeutics, Inc.
Solithromycin is designated by FDA as a Qualified Infectious Disease Product FDA has granted Priority Review and Fast Track designation for solithromycin IV and capsules for the treatment of CABP ...
Cempra to Report First Quarter 2016 Financial Results
25 avr. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Participate in Nature's Webcast on Combating Antibiotic Resistance on March 9
08 mars 2016 16h10 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., March 08, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Fourth Quarter and Full Year 2015 Financial Results
17 févr. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic...
The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra’s Oral Solithromycin in Community-Acquired Bacterial Pneumonia
05 févr. 2016 07h00 HE
|
Melinta Therapeutics, Inc.
Solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin, a potent fluoroquinolone Cempra plans to complete a New Drug Application (NDA) submission to the FDA...
Cempra to Present at the Leerink Partners 5th Annual Global Healthcare Conference
03 févr. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...